Clozapine - CAS 5786-21-0
Catalog number: 5786-21-0
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C18H19ClN4
Molecular Weight:
326.82
COA:
Inquire
Targets:
Dopamine Receptor
Description:
Clozapine is an atypical antipsychotic drug by acting as a 5-HT antagonist, used in the treatment of schizophrenia.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
HF 1854, LX 100-129
MSDS:
Inquire
1.Very Low Dose Amitriptyline for Clozapine-Associated Sialorrhea.
Sinha S1, Simlai J2, Praharaj SK3. Curr Drug Saf. 2016 Apr 26. [Epub ahead of print]
Clozapine is the antipsychotic of choice for resistant schizophrenia, but its widespread use is limited by adverse effects. Sialorrhea is a common and troublesome adverse effect seen with clozapine which leads to poor compliance. Several treatment strategies are advocated, no single treatment is considered superior. Amitriptyline, a tricyclic antidepressant, has been found to be useful for clozapine-associated sialorrhea at 87-100 mg per day. We report the effect of very low dose amitriptyline (10 mg per day) in a patient with clozapine-associated sialorrhea. There was rapid and complete resolution of sialorrhea after three days without any emergent adverse effect.
2.Use of Clozapine for Borderline Personality Disorder: A Case Report.
Amamou B1, Salah WB1, Mhalla A1, Benzarti N1, Elloumi H1, Zaafrane F1, Gaha L1. Clin Psychopharmacol Neurosci. 2016 May 31;14(2):226-8. doi: 10.9758/cpn.2016.14.2.226.
Patients with borderline personality disorder (BPD) show significant impairment in functioning, particularly in the interpersonal and social domains. Prior reports suggest that clozapine may be effective in the management of BPD. We present the case of a patient with BPD who experienced persistent suicidal ideation and was treated with clozapine at a state psychiatric hospital. After treatment failure with other psychotropic medications, clozapine medication was initiated; not only did suicidal ideation cease, but social and professional functioning also greatly improved to the point of no longer requiring intensive levels of observation or restrictive procedures. Clozapine appears to be efficacious in the management of suicide attempts and self-injurious behavior. Moreover, it appears to be promising as a therapeutic measure for ameliorating the global functioning of patients with severe BPD. Larger, randomized, blinded, and controlled prospective studies are needed to confirm these findings and to determine optimal dosage.
3.Late Onset Agranulocytosis with Clozapine Associated with HLA DR4 Responding to Treatment with Granulocyte Colony-stimulating Factor: A Case Report and Review of Literature.
Singh A1, Grover S1, Malhotra P2, Varma SC2. Clin Psychopharmacol Neurosci. 2016 May 31;14(2):212-7. doi: 10.9758/cpn.2016.14.2.212.
Agranulocytosis as a side effect of clozapine has been reported to be associated with initial phases of treatment, i.e., first six months. Agranulocytosis with clozapine during the initial phases of treatment has been linked to genetic vulnerability in the form of variations in the human leukocyte-antigen haplotypes. However, there is limited literature on late onset agranulocytosis with clozapine and this has very rarely been linked to human leukocyte-antigen haplotypes vulnerability. In this report we review the existing data on late onset agranulocytosis with clozapine and describe the case of a young man, who developed agranulocytosis with clozapine after 35 months of treatment and was found to have genetic vulnerability in form of being positive for HLA DR4. This case highlights underlying autoimmune immune mechanism in clozapine-induced agranulocytosis and the need for frequent blood count monitoring on clozapine even after the initial 6 months of starting treatment especially in patients with genetic vulnerability to develop this condition.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Dopamine Receptor Products


CAS 2934-97-6 Tetrahydropalmatine

Tetrahydropalmatine
(CAS: 2934-97-6)

Tetrahydropalmatine is isolated from the Chinese herb corydalis and acts as a striatal dopamine D2 receptor antagonist in rats. Tetrahydropalmatine exhibits ana...

CAS 104632-27-1 Pramipexole impurity D

Pramipexole impurity D
(CAS: 104632-27-1)

The dihydrochloride salt form of dexpramipexole, also known as R-(+)-Pramipexole, is one of the impurities of pramipexole. It coule be used as a negative contro...

Brexpiprazole
(CAS: 913611-97-9)

Brexpiprazole, a novel atypical antipsychotic drug, is a D2 dopamine partial agonist called serotonin-dopamine activity modulator (SDAM). It is approved for the...

CAS 162408-66-4 GR 103691

GR 103691
(CAS: 162408-66-4)

GR 103691 is a potent dopamine D3 receptor antagonist.

CAS 62421-54-9 TL 102 hydrobromide

TL 102 hydrobromide
(CAS: 62421-54-9)

TL 102 hydrobromide is a dopamine receptor agonist.

CAS 220941-93-5 CP 226269

CP 226269
(CAS: 220941-93-5)

CP 226269 is a selective dopamine D4 agonist.

CAS 67227-56-9 Fenoldopam

Fenoldopam
(CAS: 67227-56-9)

Fenoldopam is a selective D1 receptor partial agonist, binds to α2-adrenoceptors, increasing renal blood flow used as an antihypertensive agent.

CAS 150542-92-0 N 0426 hydrochloride

N 0426 hydrochloride
(CAS: 150542-92-0)

N 0426 hydrochloride is a dopamine receptor agonist.

CAS 96333-04-9 N 0430 hydrobromide

N 0430 hydrobromide
(CAS: 96333-04-9)

N 0430 hydrobromide is a monoamine oxidase (MAO) inhibitor and a dopamine agonist.

CAS 182210-74-8 (S)-5-Hydroxy-DPAT hydrobromide

(S)-5-Hydroxy-DPAT hydrobromide
(CAS: 182210-74-8)

A potent and selective dopamine (DA) D2 receptor agonist.

CAS 10457-90-6 Bromperidol

Bromperidol
(CAS: 10457-90-6)

Bromperidol, a derivative of butyrophenone, is an antipsychotic commonly used in the treatment of schizophrenia as it could bind to the D2 dopamine and 5-HT2A s...

CAS 32672-69-8 Mesoridazine besylate

Mesoridazine besylate
(CAS: 32672-69-8)

Mesoridazine besylate, a phenothiazine dopamine receptor anatagonist, has been described to demonstrate inhibition for D2DR and D4DR. High affinity for the clon...

CAS 13575-86-5 6,7-Dihydroxy-2-aminotetraline hydrobromide

6,7-Dihydroxy-2-aminotetraline hydrobrom
(CAS: 13575-86-5)

6,7-Dihydroxy-2-Aminotetraline hydrobromide is a dopamine receptor agonist.

CAS 1148156-63-1 ST-836

ST-836
(CAS: 1148156-63-1)

ST-836, a dopamine receptor ligand, might have similar effect with dopamine and probably useful as an antiparkinsonian agent.

CAS 364-62-5 Metoclopramide

Metoclopramide
(CAS: 364-62-5)

Metoclopramide is used mostly for stomach and esophageal problems by bind to dopamine D2 receptors with nanomolar affinity (Ki 28.8 nM)

CAS 71675-85-9 Amisulpride

Amisulpride
(CAS: 71675-85-9)

Amisulpride is an atypical antipsychotic used to treat psychosis in schizophrenia and episodes of mania in bipolar disorder.

CAS 64656-40-2 3-[2-(Diproplyamino)ethyl]phenol hydrobromide

3-[2-(Diproplyamino)ethyl]phenol hydrobr
(CAS: 64656-40-2)

A dopamine receptor agonist.

CAS 125572-93-2 Rotigotine Hydrochloride

Rotigotine Hydrochloride
(CAS: 125572-93-2)

The hydrochloride salt form of Rotigotine which is a dopamine D2 and D3 receptor agonist and has been shown to be effective in the treatment of Parkinson's dise...

CAS 148408-65-5 Sunepitron hydrochloride

Sunepitron hydrochloride
(CAS: 148408-65-5)

Sunepitron hydrochloride is a potent and selective serotonin 5-HT1A autoreceptor agonist, α2-adrenergic antagonist, and dopamine D2 agonist. The phase III clini...

NS-2359
(CAS: 195875-68-4)

NS-2359, a serotonin-norepinephrine-dopamine reuptake inhibitor, may be able to reduce cocaine withdrawal symptoms, reduce cocaine craving and reduce cocaine-in...

Chemical Structure

CAS 5786-21-0 Clozapine

Quick Inquiry

Verification code

Featured Items